Home › NDC Lookup › RxCUI directory › RxCUI 1482517

Eslicarbazepine acetate 400 MG Oral Tablet [Aptiom] — RxCUI 1482517

RxNorm drug concept · Semantic branded drug
RxCUI 1482517 Semantic branded drug · SBD ● Current RxNorm concept 5 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1482517
Official nameEslicarbazepine acetate 400 MG Oral Tablet [Aptiom]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAptiom 400 MG Oral Tablet; Aptiom 400 MG Oral Tablet, Once Daily
FDA products mapped5
Package NDCs mapped9
Reported Medicaid activity (SDUD)38,134 prescriptions · 43 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Eslicarbazepine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Sure. Eslicarbazepine acetate (brand name Aptiom) is specifically approved to treat partial-onset seizures — that's when a seizure starts in just one area of the brain rather than...
  • What exactly is this medicine for? My doctor said it's for seizures — can you tell me more?
  • Good news — food doesn't affect how this medicine works, so you can take it with or without a meal, whichever is easier for you. It's taken just once a day, which most people find...
  • Can I take this pill with food, or does it have to be on an empty stomach?
📖 Read our full Eslicarbazepine guide →

🕸️ Concept Web — How Eslicarbazepine acetate 400 MG Oral Tablet [Apti... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Eslicarbazepine acetate 400 MG Oral Tablet [Aptiom] RxCUI 1482517

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Eslicarbazepine 1482502
    • Eslicarbazepine acetate 1482501
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Aptiom 1482508
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Eslicarbazepine Oral Tablet 1482506
    • Eslicarbazepine acetate Oral Tablet 2647024
    • Eslicarbazepine Oral Product 1482504
    • Eslicarbazepine Pill 1482505
    • Eslicarbazepine acetate Oral Product 2662353
    • Eslicarbazepine acetate Pill 2660612
    • Eslicarbazepine Oral Tablet [Aptiom] 1482510
    • Eslicarbazepine acetate Oral Tablet [Aptiom] 2654181
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 2

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 16 of 21 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

5 products · 9 package NDCs
9 package NDCs map to RxCUI 1482517 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
63402-0202-28 4 BLISTER PACK in 1 CARTON (63402-202-28) / 7 TABLET in 1 B... Aptiom Sumitomo Pharma America, Inc. 2017-09-13
63402-0202-30 30 TABLET in 1 BOTTLE (63402-202-30) Aptiom Sumitomo Pharma America, Inc. 2014-04-07
63402-0204-28 4 BLISTER PACK in 1 CARTON (63402-204-28) / 7 TABLET in 1 B... Aptiom Sumitomo Pharma America, Inc. 2014-04-07
63402-0204-30 30 TABLET in 1 BOTTLE (63402-204-30) Aptiom Sumitomo Pharma America, Inc. 2014-04-07
63402-0206-28 4 BLISTER PACK in 1 CARTON (63402-206-28) / 7 TABLET in 1 B... Aptiom Sumitomo Pharma America, Inc. 2014-04-07
63402-0206-60 60 TABLET in 1 BOTTLE (63402-206-60) Aptiom Sumitomo Pharma America, Inc. 2014-04-07
63402-0208-28 4 BLISTER PACK in 1 CARTON (63402-208-28) / 7 TABLET in 1 B... Aptiom Sumitomo Pharma America, Inc. 2014-04-07
63402-0208-30 30 TABLET in 1 BOTTLE (63402-208-30) Aptiom Sumitomo Pharma America, Inc. 2014-04-07
63402-0248-56 4 BLISTER PACK in 1 CARTON (63402-248-56) / 1 KIT in 1 BLIS... Aptiom Sumitomo Pharma America, Inc. 2014-04-07
Observed labelers: Sumitomo Pharma America, Inc. (9) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.